TriGemX Bio raises $94 million to fund Phase III trials of oral migraine drug elismetrep. Discover the investors backing the program and what comes next.
Samsung Bioepis and Teva expanded their partnership to develop and commercialize up to six biosimilar candidates. See which ...
Astrocyte Pharmaceuticals secures $9.5M Series B funding to advance AST-004 into Phase II trials for concussion and TBI ...
CMS finalized the mandatory GLOBE model, linking Medicare Part B rebates to international drug prices starting in 2027. See ...
Foghorn Therapeutics is cutting about 40% of its workforce after ending FHD-909 and other SMARCA2 programs with Lilly. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results